U.S. drug company Merck & Co on Monday received approval from the European Commission to market its Ebola vaccine after a European drug panel backed the first-ever vaccine against the lethal virus.
The vaccine, Ervebo, is permitted for individuals aged 18 years and older and has already been used beneath emergency pointers to try to shield against the spread of a deadly Ebola epidemic in the Democratic Republic of Congo.
The U.S. well-being regulators are also reviewing the shot, and a decision is anticipated in the first quarter of 2020.
The Ebola virus causes a hemorrhagic fever; is contagious through direct contact with body fluids. It kills around half of the sufferers.
Since the middle of last year, the Congo Ebola outbreak has killed over 2,100 individuals, making it the second-largest Ebola outbreak in history, after the 2013-16 epidemic in West Africa that killed over 11,300.
“The EU is supporting worldwide efforts to combat Ebola on all fronts, from vaccine development to delivering humanitarian help on the ground,” EU Ebola Coordinator Christos Stylianides mentioned in a statement dated November 10.
Merck has stated its priority was to get a regulatory license of its Ervebo manufacturing site in Germany in order that licensed supply of the vaccine “can be used to support global public health preparedness”.